Latest

2 stories

Hide weekly roundups

Thursday, August 6

Prime Medicine clears path for two liver programs, gains RMAT for PM359

Global Phase 1/2 clearances for Wilson disease and a favorable arbitration outcome with Beam Therapeutics advance Prime Medicine's pipeline as cash runway extends into 2027.

SEC filing

Tuesday, August 4

Quarterly updateBeam Therapeutics Inc.

Beam doses first patient in pivotal BEAM-302 cohort, updates PKU and sickle cell timelines

The company reported second-quarter 2026 results alongside progress on its AATD, PKU, and sickle cell programs, with $1.2 billion in cash guided to last into mid-2029.

SEC filing